World Health Organization. 2018. Hexavalent vaccine: less injections and more protection for babies. https://www.afro.who.int/news/hexavalent-vaccine-less-injections-and-more-protection-babies
World Health Organization. 2004. Hexavalent vaccines. https://www.who.int/groups/global-advisory-committee-on-vaccine-safety
World Health Organization. 2024. Training Package on Polio Vaccination and for switching to Hexavalent Vaccine [Technical document].https://www.who.int/publications/
Capeding, Maria Rosario, Cadorna-Carlos, Josefina, Book-Montellano, May & Ortiz, Esteban. (2008). Immunogenicity and safety of a DTaP–IPV//PRP~T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bulletin of the World Health Organization, 86 (6), 443 - 451. World Health Organization. http://dx.doi.org/10.2471/BLT.07.042143
Summary of recent issues considered by four national immunisation technical advisory groups (NITAGs) and WHO immunisation-related advisory committees Prepared by the National Centre for Immunisation Research and Surveillance (NCIRS) Period of review: 22/08/2021 – 20/01/2022
https://www.gavi.org/our-support/guidelines/hexavalent-vaccine-programme-
HEXAVALENT SCHEDULE
Starting from 6 weeks of age (minimum), the World Health Organization (WHO) recommends a hexavalent vaccine schedule of 3 doses with a minimum interval of 4 weeks between doses, and a booster dose given at least 6 months after the third dose. Illustrative schedules are shown below
Geddes, L. 2023. New hexavalent vaccines are coming: What impact could they have? https://www.gavi.org/vaccineswork/
The Vaccine Knowledge Project. 2023. The hexavalent DTaP/IPV/Hib/HepB (6 in 1) combination vaccine
Knuf, M., Charkaluk, M. L., The Nguyen, P. N., Salamanca de la Cueva, I., Köbrunner, P., Mason, L., ... & Berlaimont, V. (2023). Penta-and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g: A systematic literature review. Human Vaccines & Immunotherapeutics, 19(1), 2191575. https://doi.org/10.1080/21645515.2023.2191575
Tormans, G., Doorslaer, E. V., Damme, P. V., Clara, R., & Schmitt, H. J. (1998). Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. European journal of pediatrics, 157, 395-401.
Chitkara, A. J., Parikh, R., Mihalyi, A., & Kolhapure, S. (2019). Hexavalent vaccines in India: current status. Indian Pediatrics, 56, 939-950.
GAVI. 2018. Vaccine investement: Gavi’s vaccine investment strategy determines which vaccines are made available to countries through our vaccine support programmes. https://www.gavi.org/our-alliance/strategy/vaccine-investment-strategy-2018
Public Health Agency, 2018. The hexavalent DTaP/IPV/Hib/HepB (6 in 1) combination vaccine Information for healthcare professionals about the inclusion of hepatitis B vaccine in the routine infant immunisation programme. https://www.publichealth.hscni.net/sites/default/files/The%20hexavalent_DTaP_IPV_Hib_HepB_combo_factsheet_0.pdf
